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Circulating IgA-bearing immune complexes/aggregates in SLE nephri-
tis. M. K. Dasgupta, M. Larabie, T. K. Shnitka, I. Love, T. Kovitha-
vongs, and J. B. Dossetor. Departments of Medicine and Pathology,
University of Alberta, Edmonton, Canada. We have recently studied
the prevalence of IgA-bearing immune complexes or aggregates (1gA-
CIC/A) using a modification of Raji-RIA and a solid-phase C3 depen-
dent assay (SP-RIA-IgA). These IgA specific tests have been compared
with CIC-IgG by classical Raji and CIC-IgG/M, Clq-binding assay, and
serum IgA. Prevalence for IgA-CIC/A in IgA-GN is 70% (with correla-
tion with raised serum IgA (P < 0.025) and, in SLE/GN, is 46% (with no
correlation to serum IgA (P > 0.25). The SLE/GN group has been
broken down into mesangial-proliferative, membranous. and diffuse
proliferative forms, as seen below:
Type of SLE/ON
Sam-
pIes
no.
IgG/M-CIC'
Raji-IgG Clq-BA
IgA-CIC"
Raji-IgA &
SP-RIA-IgA
Mesang. prolif. (N = II) 46 78% 26% 83%
Membranous (N = 7) 19 79% 21% 37%
Duff. prolif. (N = 16) 137 62% 23% 31%
a % positive
The high incidence of IgA-CIC/A in mesang-prolif SLE/GN, with low
incidence in the other two forms, suggests that the mesangial form has a
different immuno-pathogenesis which will be correlated with a clinical
course.
Sex differences in childhood lupus nephritis (LN). G. S. Arbus, P.
Thorner, D. Celermajer, and R. Baumal, Departments of Pediatrics
and Pathology, The Hospital for Sick Children, Toronto, Ontario,
Canada. Renal biopsy specimens and the renal function of 60 children
with SLE were evaluated, to determine whether LN was more severe in
either sex. We found:
Patients Males Females
Class of lupus
nephritis No. % No. % No. %
(1) Normal
(2) Mesangial
(3) Focal prolif.
(4) Diffuse prolif.
(5) Membranous
Total
Ten males (67%) and nine females (20%) showed diffuse proliferative
LN (P < 0.01). Renal status at presentation and outcome were graded
(I) normal; (2) mild (up to 2+ proteinuria, hematuria and casts); (3)
moderate (between mild and severe); (4) severe (nephrotic, abnormal
serum creatinine, hypertension); (5) terminal (death in renal failure, or
dialysis/transplant). We found clinically that:
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status
Presentation Outcome
Boys Girls Boys Girls
Normal 5 (33%) 22 (49%) 3 (25%) 28 (68%)
Mild I (7%) 13 (28%) 1 (8%) 11(27%)
Moderate 1 (7%) 3 (7%) 6 (50%) 2 (5%)
Severe 8(53%) 7(16%) 1 (8%) 0 (0%)
Terminal 0 0 I (8%) 0
At onset, 53% males and 16% females had severe illness (P < 0.05);
64% males and 5% females had a moderate or worse outcome (P <
0.001). This study shows that more males than females (I) suffer from
diffuse proliferative LN and they (2) present and terminate more
severely.
Intra-platelet serotonin concentrations in SLE. B. R. Riche, R. F.
Plomley, D. A. Bell, M. Harth, and W. F. Clark. Department of
Medicine, University of Western Ontario, London, Ontario, Canada.
We undertook a study to assess the intra-platelet serotonin (1-PS)
concentration in SLE patients with and without renal disease. All
patients met a minimum of 4 ARA criteria for the diagnosis of SLE and
had at least one episode of ANA positivity complement depression
and elevated DNA binding. Renal SLE was defined as the presence of
greater than I g of proteinurial24 hr coupled with biopsy evidence of
nephritis. Nonrenal SLE was defined as less than 200 mg of protein-
urial24 hr, less than 10 RBCs or WBCs/hpf, no RBC casts, and a serum
creatinine less than 1.4 mg%. The 1-PS concentration in 40 patients with
SLE was significantly lower at 412 ng/109 platelets than the 663
ng/l09 platelets observed in 40 age- and sex-matched control subjects(P < 0.001). Both renal (N = 20) and nonrenal (N = 20) SLE patients
had a significantly lower 1-PS concentration than control subjects. The
mean I-PS concentration of the renal patients of 350 ng/109 platelets
was significantly lower (P < 0.05) than the nonrenal SLE patients
whose 1-PS was 473 ng/109 platelets. This difference was not related to
disease activity since in both groups disease activity was equal by two
different scales. In fact, the difference between renal versus nonrenal
SLE achieved a higher level of significance (P < 0.01) when controlled
for disease activity. Our findings are compatible with the concept of
platelet involvement in intrarenal immune complex deposition in SLE
nephritis.
Kidney international. Vol. 25 (1984), pp. 993—1000
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4 7 2 12 2 4 Dietary control in assessing hypertension and nephrolithiasis. D.
23 38 1 7 22 50 Hanley, M. Watanabe, and H. Mandin. Department of Medicine,II 18 1 7 10 22 University of Calgary, Calgary, Alberta, Canada. After a recent report,
19 32 10 67 9 20 we looked for a relationship between urinary calcium (Ca) and
3 5 1 7 2 4 urinary sodium (Na) excretion in a group of calcium stoneformers
60 100 /5 /00 45 100 entering our nephrolithiasis investigative protocol. In 40 patients we
found a significant positive correlation r = 0.39 (P < 0.01) between Na
and Ca while patients were on their regular diets. With urine Na less
than 300 m the relation was linear, with a 10 m increment in Na
corresponding to a 0.17 m increment in Ca. In an attempt to then
address the issue of whether changes in sodium intake or excretion may
be related to changes in PTH activity, we retrospectively examined Na
and cAMP excretion in 93 men and women entering an investigative
protocol for patients with hypertension. The patients were given a
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prepared 10 mt and 100 m Na diet for 4.5 days each, with 24-hr urine
Na and cAMP collected for the last 24 hr of each diet. Although cAMP
excretion was significantly higher (P < 0.05) on the low Na diet than on
the high Na diet (3.15 vs. 2.74 smoles creatinine), repeated measures of
analysis of covariance indicated we could not relate the difference in
cAMP to the difference in Na excretion between the two diets. The low
Na diet has 13 mt Ca and the high Na diet has 22 mi Ca which may be
the cause of the higher cAMP on the low Na diet. We conclude that
because of the link between Na and Ca excretion and recent interest in
PTH as a vasodilator, dietary protocols for investigating nephrolithiasis
and hypertension should control for Na and Ca intake, respectively.
Urate handling in calcium stoneformers. V. R. Walker and R. A. L.
Sutton. Department of Medicine, University of British Columbia,
Vancouver, British Columbia, Canada. Uric acid disorders may con-
tribute to Ca stone formation in idiopathic Ca stoneformers (SF) even in
the absence of hypercalciuria. The purpose of the present study was to
determine if there are differences in renal urate handling between SF
and normal subjects (N). In 2-hr fasting urine collections in 50 SF (80%
male) and 20 N (75% male), we observed no differences in urine urate
excretion, and serum (s) urate (SF. 5.6 0.2 vs. 5.8 0.3 mg/dl) and
FE urate (SF, 6.8 0.4 vs. N. 7.0 0.7% mgldl) were also similar.
Furthermore, these values did not differ between the groups during
normal diet. However, in 24-hr urine samples and fasting blood samples
after 4 days of high dietary Ca, we observed that SF (N = 12), in
contrast to N (N = 8), (I) increased s urate from 5.9 0.3 mg/dl (while
on a normal diet) to 6.7 0.3 mg/dl, P < 0.01, (2) decreased urine urate
excretion (P < 0.05), and (3) had a lower FE urate than N (4.8 0.3 vs.
7.0 0.9%, P <0.05). SF also increased s Ca(P <0.01) and decreased
UcAMP (P < 0.001) (not significant in N). Urine phosphate was also
reduced in SF (P < 0.01), but urine Na did not increase as it did in N
despite a greater calciuresis in SF. These findings indicate that although
renal urate handling in SF and N is similar under normal conditions,
high dietary Ca in SF is associated with an exaggerated change in renal
urate handling as compared to N. These changes may be a direct effect
of higher serum and urine Ca in SF but may also be secondary to altered
renal transport of other urine constituents including phosphate and Na.
Comparison of medical treatments for the prevention of recurrent
calcium nephrolithiasis. D. R. Wilson, A. L. Strauss, and M. A. Manuel.
Department of Medicine, University of Toronto, Toronto, Ontario,
Canada. A randomized prospective open trial of five medical regimens
was carried out in patients with idiopathic recurrent calcium nephroli-
thiasis. Regular (Reg) treatment (extra fluids, moderate diet calcium
and oxalate restriction) was compared with regular treatment (Rx) and
hydrochlorothiazide 100 mg, or sodium phosphate 1.5 g, or magnesium
oxide 400 mg, or allopurinol 300 mg daily. Sixteen percent of the
patients were lost to follow-up. Twenty-six percent of the patients had
side effects, with 57% in the phosphate group (P < 0.02). In 94 patients,
pre-Rx data for 11.3 years (average) were compared with treatment
results greater than I year (average 2.8 years).
Reg Hct Phos Mg Allo
# Patients (Pt) 21 23 17 16 17
Pre-Rx stones/yr 0.84 0.82 0.81 0.69 1.53
#Ptrelapse 8 7 6 7 8
Stones/yr on Rx 0.32 0.15 0.32 0.63 0.48
Actual/predicted 44% 2l% 42% l02%b 34%a
Different from pre-treatment, P < 0.01.
Different from other groups, P < 0.05.
Pretreatment stone recurrence rate was higher in patients with relapse
on treatment (1.24 stones/year vs. 0.63, P < 0.001) and pre-Rx urine
calcium, uric acid, and oxalate were also higher (P < 0.05). Regular Rx
reduced stone recurrence rate by 56% and phosphate or allopurinol had
no additional effect. Magnesium was ineffective. Hydrochlorothiazide
was significantly more effective than other treatments, reducing recur-
rence rate by 79%.
Studies on mechanisms of calcium release from bone using an in vitro
bone perfusion system. P. J. Somerville and M. Kaye. Division of
Nephrology, Montreal General Hospital, Montreal, Canada. We re-
cently developed an in vitro bone perfusion system to examine calcium
release using isolated tails from rats prelabeled with 4Ca. Tails were
placed in a heated chamber and perfused via the tail artery with an
aqueous Krebs Ringer bicarbonate solution at about 100 mm Hg
pressure. Agents known to affect cell calcium transport were added to
the perfusion fluid during the second hour of a 2-hr experiment and any
change in 45Ca release was determined by measuring the 45Ca concen-
tration in the venous effluent every 10 mm. Both verapamil and
inhibitors of Ca-Na exchange were found to significantly inhibit 45Ca
release. As an example the 45Ca concentration in the effluent during the
last 10-mm period of a 2-hr experiment was 100 5.5% of the initial
concentration in a control group and 65.9 3.7% in a group in which
verapamil 104M was added to the perfusate during the second hour.
The difference between these two groups was highly significant (P <
0.001, N = 8 or 9). Similar results were noted with the Na-Ca exchange
inhibitors, quinidine and disopyramide, whereas no effect was seen with
the powerful ATPase inhibitor vanadate. A tentative conclusion from
these results is that calcium release in this system may involve transport
via slow calcium channels or Ca-Na exchange.
Bone mineral content in calcium nephrolithiasis. J. Barkin, D. R.
Wilson, A. L. Strauss, and J. Harrison. Department of Medicine,
University of Toronto, Toronto, Ontario, Canada. The role of altered
skeleton mineral metabolism in calcium nephrolithiasis has not been
determined. In vivo neutron activation analysis and whole body count-
ing were used to measure vertebral calcium content (calcium bone
index, CaBI) in 113 patients with recurrent calcium nephrolithiasis
(average nine stones in 10 years). CaBI was 0.91 0.13 (SE), significant-
ly lower than normal adults of similar age, 0.97 0.13, P <0.01. This
decrease in bone mineral in stone formers (SF) was largely due to a
decrease in male SF (0.91 SF vs. 0.98 normals, P < 0.02) rather than
female SF (0.93 SF vs. 0.97, P = NS). CaBI in male SF was lower than
normals from age 20 to 39 (P < 0.02) and age 40 to 59 (P < 0.02). The
cause of the decrease in bone mineral in male SF is unknown. Repeat
CaBI measurements after an average follow-up of 2 years showed no
change in CaBI during treatment with dietary calcium restriction,
thiazides, or phosphate. Fasting urine calcium/creatinine (FUCa/Cr)
ratios were higher in patients with lower CaBI, r = —0.39, P < 0.01.
This renal loss of calcium could be due to a renal tubular defect or
increased bone turnover. The lack of correlation of FUCaJCr with
serum PTH or urine cyclic AMP does not support a primary renal leak
of calcium with secondary hyperparathyroidism. We conclude that
bone mineral content is reduced in male SF, possibly due to an as yet
undetermined primary abnormality of the skeleton.
Serum aluminum (Al) levels and removal of Al in CAPD patients. S.
Prichard and C. Cole. Royal Victoria Hospital, McGill University,
Montreal, Canada. High H20 Al levels are associated with dialysis
dementia and severe osteomalacia. Oral Al (phosphate binders) can also
lead to significant accumulation of tissue Al. The purpose of the present
study was to measure (I) serum Al levels in CAPD patients and assess
its relationship to oral Al load and (2) Al removal on CAPD. Fifteen
CAPD patients, six female and nine male, with a mean age of 57.6
12.5 years were studied. They had been on CAPD for 4 to 48 months
(mean, 20.9 12.7 months). Mean Ca equaled 8.84 0.77 mgm%;
mean P, 4.88 1.39 mgm%; mean Alk. P'ase, 210 123 lU; and mean
Mg, 2.57 0.5 mEq/liter. All subjects ingested Al in the form of
Al(OH)1 or magdalate (Riopan—l patient) with total ingested Al ranging
from 96 to 2838 g: mean = 984 772 g at mean rate of 48.5 24
g/dialysis month. The average serum Al level was 66 Wliter, range 20
to 160 pg/liter (N <20 zg/liter), with 8 of 13 greater than 50 pg/liter. The
serum Al was significantly correlated with the total ingested Al load (r
= 0.80, P < 0.01). Al removal by CAPD was studied in nine patients.
The others had only drainage Al levels measured. There was almost
negligible removal of Al across the peritoneum. The maximum 24-hr Al
load removed was 360 zg. The average was less than 60 sg/day.
Equilibrium between dialysate and serum Al was never reached at the
time of exchange (6 to 8 hr). Inflow Al was less than 10 pg/liter. We
conclude that orally ingested Al in CAPD patients leads to significantly
elevated serum Al levels. The removal of Al by CAPD is minimal.
Vitamin D can reverse osteomalacia in aluminum (Al) loaded vitamin
D-deficient rats. A. B. Hodsman. Department of Medicine, University
of Western Ontario, London, Canada. Dialysis osteomalacia (OM) has
Abstracts 995
been associated with accumulation of Al in bone and relative hypercal-
cemia; in a previous study we showed accelerated uptake of Al by
osteoid (OS) matrix in rats with nutritional OM. This study was
designed to determine if Al-loaded OS matrix would mineralize after
correction of D-deficiency with 2SOHD. D-deficient rats received A13*
0.75 mg/day i.p. for 30 days (D—Al+), together with a control group
who did not receive Al (D—Al—). Two further groups were treated
similarly, but then received parenteral 250HD, 10 ng/day for another 30
days (D+Al+ and D+Al—). At sacrifice, serum calcium (sCa). alkaline
phosphatase (sAP), and bone Al (bAl) content (expressed as Al3 mg/kg
bone wt) were measured. Histological measurements in tibial diaphysis
included histochemical Al stain (Al mm2/mm2 OS), relative osteoid
volume (ROV%), osteoid seam width (OSW), and presence of double
tetracycline labels (TCL) given I and 3 days before sacrifice. Resultsa
are shown in the table:
D-Al+ D-Al-
sCa (mg/dl) 7.7 0.5" 5.4 0.l
sAP (iu/l) 388 61 421 31
bAl (mg/kg)
bAl mm2/mm2
928 78"
0.21 0.09
16 2
negative
ROV (%) 24.3 4,Øb.d 27.6 1.4'
OSW () 5.3 0.6"" 6.3 0.3'
TCL none none
D+Al+ D+Al-
sCa (mg/dl) 10.0 0.1 9.9 0.1
sAP (iu/l) 134 4 197 18
bAl (mg/kg)
bAl mm2/mm2
239 15
negative
5.7 0.7
negative
ROV (%) 5.2 0.3' 5.1 0.9
OSW () 2.1 0.1cd 2.3 0.1'
TCL present present
aMean±SEM,N =6;bvs.cP<0.05,vs,NS.
In conclusion, (I) Al+D—rats have higher sCa levels than Al—D—; (2)
despite high levels of bAl and a +ve Al stain in D—Al+ rats, treatment
with 2SOHD can reduce sAP, improve mineralization, and lead to
reduced bAl content. Thus, the presence of Al in bone does not
necessarily preclude normal mineralization.
Toxicity of oral aluminum (Al). S. Prichard, P. Barré, A. Hodsman,
and M. Kaye, Department of Medicine, McGill University, Montreal
and University of Western Ontario, London, Ontario, Canada. Severe
osteomalacia has been associated with high H2O and bone Al. This
study assesses the relationships of ingested Al (P binders) to bone Al
content using histological techniques (aluminum staining) and bone Al
levels. Fourteen normal (N) subjects, eight patients with chronic renal
failure (CRF), mean serum Cr 11.5 mgm%, and 18 dialysis patients
dialyzed against water with Al level less than 10 gJliter were studied.
No N ingested Al. Al staining was negative in all N biopsy specimens:
Mean bone Al = 15.9 7 mg/kg dry bone wt. Seven CRF had no AL
intake and had negative Al stain: Mean bone Al = 20.0 8.4 mg/kg dry
bone. One CRF had 2+ Al stain after 1.5 kg Al intake. One had a follow-
up biopsy after ingestion of 1.03 kg of Al at a rate of 90 glmonth showing
3+ staining and an At content equaled 323.8 mg/kg (first biopsy Al =
28.9 mg/kg). The dialysis group had ingested 0 to 15.73 kg Al prior to
biopsy. There is a significant relationship between bone staining versus
total Al ingestion (r = 0.57, P < 0.05), bone staining versus Al
ingestion/month (r = 0.81, P < 0.OOl)and Bone Al content vs Al/month
(r = 0.64, P < 0.05). Dialysis who never ingested Al (N = 5) had a bone
Al = 23.6 1.6mg/kg similar to controls and CRF (no Al). Ten of the 13
dialysis patients with positive Al staining had bone pain myopathy
compared with none of the Al negative dialysis patients. Biochemistry,
PTH, bone scans, and x-rays were similar in these two dialysis groups.
We concluded that ingested Al is significantly related to bone Al
accumulation.
Renal enzymes during experimental diabetes mellitus. G. Lemieux, M.
RengelAranda, P. Fournel, andC. Lemieux. Renal Laboratory, Hotel-
Dieu Hospital and Department of Medicine, University of Montreal,
Montreal, Canada. The activity of enzymes concerned with ammonia-
genesis, gluconeogenesis, and glycolysis was measured in the renal
cortex and the liver of rats made diabetic with streptozotocin. Five
groups of animals were studied: normal, diabetic normoglycemic (insu-
lin-treated), diabetic hyperglycemic, diabetic ketoacidotic, and also rats
made acidotic with ammonium chloride. In the kidney, glutaminase I
rose during ketoacidosis and ammonium chloride acidosis. Glutamate
dehydrogenase rose only during the administration of ammoniurn
chloride. Glutamine synthetase did not change. Phosphoenolpyruvate
carboxykinase (PEPCK) rose in hyperglycemic animals and more so
during ketoacidosis and NH4CI acidosis. It also rose in the liver of the
diabetic animals. Hexokinase activity in the kidney rose in diabetic
insulin-treated normoglycemic animals and also during ketoacidosis.
The same pattern was observed in the liver. Phosphofructokinase
activity was elevated in the kidney and liver in all groups of experimen-
tal animals. Fructose-l,6-diphosphatase, malate dehydrogenase, malic
enzyme, and lactate dehydrogenase did not vary significantly in the
kidney and liver. The present study indicates that glutaminase I is
associated with the first step of increased renal ammoniagenesis during
diabetic ketoacidosis. PEPCK activity is influenced both by hypergly-
cemia and ketoacidosis, acidosis playing an additional role. Insulin
appears to prevent renal gluconeogenesis and to favor glycolysis. The
latter seems to remain operative in hyperglycemic and ketoacidotic
diabetic animals.
Effect of pH on the permeability of the distal nephron to prostaglandins
E2 (PGE2) and F2a (PGF2a). L. N. Peterson, J. G. Gerber, and A. S.
Nies. Departments of Pediatrics and Physiology, University of Ottawa,
Ottawa, Ontario, Canada, and the Department of Medicine, University
of Colorado, Denver, Colorado. Since PGE-, and F2a are fatty acid
derivatives, changes in pH might be expected to alter their efflux from
the distal nephron. To assess this possibility on the single nephron
level, 20-ni samples of 3H-PGs were microinjected into early distal
tubules, and their recovery in the urine was compared to that of '4C-
inulin, in HCO3-loaded or acid-loaded rats. Although urine flow rates
were similar, there was a striking elevation in pH in the HCOrloaded
rats (7.87 0.017 vs. 5.66 0.067, P < 0.001). Also, to examine
luminal factors acting on PG movement, collections of early distal fluid
were made and ['CO] was measured by microcalorimetry. There was
no difference in distal flow rate, while, ['CO2I and calculated pH were
significantly elevated in the bicarbonate-loaded rats (7.66 0.029 vs.
6.07 0.093, P < 0.001).
3H PG/14C Inulin x 100
Acid-loaded HCO-loaded
PGE2
PGF2s
96.2 1.25
(17)
96.9 0.76
(16)
100.9 l.43a
(19)
98.1 0.61
(21)
P < 0.05 vs. PGE2 acid-loaded.
The microinjection experiments show (see table) that fractional reab-
sorption is only 2 to 4% for PGE2 and F2a. This suggests that
permeability of the distal nephron is normally extremely low, but
nevertheless, permeability to PGE2 can be further decreased when
tubular fluid pH is elevated.
Evidence of enhanced renal potassium transport in magnesium defi-
cient rats. R. A. L. Sutton, V. Mavichak, D. M. Feuchuk, N. L. M.
Wong, and J. H. Dirks. Department of Medicine, University of British
Columbia, Vancouver, British Columbia, Canada. Hypokalemia and
potassium (K) depletion is a prominent manifestation of the magnesium
(Mg) deficiency state. This has been attributed to renal K wasting since
replacement of K may be rapidly excreted in the urine until Mg
deficiency is restored. We therefore examined renal K transport in Mg
deficient rats (D, N = II). Three-phase clearance studies were per-
formed in acutely thyroparathyroidectomized (TPTX) rats fed a low
Mg, low calcium diet of normal K content for 7 days. Control rats (C, N
= II) were fed a normal diet. A first control phase with normal saline
infusion (77 j.d/min) was followed by potassium chloride (KCI) infusion
at 7.7 and 15.4 M/min. In the three successive phases, plasma (P) Mg
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was 0.19 0.02, 0.20 0.03 (P>0.05) and 0.21 0.02mM (P>0.05)
in D, and 0.57 0.02, 0.53 0.02 (P >0.05). and 0.52 0.01 mvi (P <
0.01) inC. respectively. PK was 3.3 0.1,4.9 0.2(P <0.001) and 7.8
0.3 (P <0.001) in D and 4.0 0.1,5.5 0.1 and 7.3 0.3 (P <0.001)
m in C, respectively. In response to KCI infusion fractional excretion
ofK increased from 2.9 0.3 to 7.5 0.8 (P < 0.00l)to 25.2 3.8% (P
< 0.001) in D and from 5.5 0.7 to 22.8 2.4 (P < 0.001) to 58.7
3.9% (P < 0.001) in C, respectively. Absolute K reabsorption was
consistently higher in D than C at any level of K. Thus, Mg deficient
hypokalemic rats revealed no evidence for renal K wasting. The data
suggest that renal K reabsorption was actually enhanced compared with
normal rats. (P values were compared with the control phase.)
In vivo study of renal mitochondrial permeability to glutamine in the
rat. N. Khourv, N.Duong, P. Vinay, and A. Gougoux. Departments of
Medicine and Physiology, University of Montreal, Montreal, Canada.
Tissue (cytoplasmic glutamine) (TGln) in proximal tubular cells is
separated from the mitochondrial glutaminase enzyme initiating its
metabolism by the mitochondrial membrane. The increased Gin break-
down observed during acidosis may thus be related to permeability
changes of this membrane for Gin. Four indirect criteria assessing this
permeability in the rat kidney in vivo were studied: (I) the change in
TGIn following acid-base disturbances; (2) the increment or TGIn
following a standard intravenous Gin load; (3) the generation of
glutamate (Glu): and (4) ammonia following this maneuver. TGIn was
higher and a standard load of Gin elevated more TGIn during alkalosis
than during acidosis. Following the load, Glu accumulated and ammo-
nia was produced only when metabolic or respiratory acidosis was
superimposed. Bicarbonate but not a-ketoglutarate (aKG) suppressed
these effects. The response of acute acidosis + Gin load in normal rats
(normal glutaminase) and rats recuperating (24 hr) from chronic (6 days)
acidosis (increased glutaminase) was similar. We conclude (1) that the
ammoniogenic flux was not substrate-regulated in the rat, (2) that acid-
base changes modify mitochondrial permeability to GIn in vivo, (3) that
aKG plays a minor role in viva in modulating this permeability, (4) that
mitochondrial glutamine entry limits the ammoniogenic flux in normal
and alkalotic rats while glutamate metabolism limits this flux in acidotic
animals, and (5) that mitochondrial transport and deamidation are due
to distinct proteins.
21 deceased members. Among living members, 27 had known APKD,
60 of an additional 174 studied by ultrasound had definite APKD, 17
refused and 95 were unavailable for study. Fourteen of the deaths were
attributed to APKD. All who had APKD diagnosed, a predicted
proportion of those unavailable for study, and those who had died
without study for APKD formed the group at risk for ESRD from birth
and thus comprise an inception cohort (N = 132). The outcome event
was ESRD requiring dialysis or transplantation, or death due to APKD.
The product limit estimate was used to determine the time-to-event
(ESRD) curve. The youngest subject to develop ESRD was 36 years
old. The probability of developing ESRD was 23% by age 50, 43% by
age 58, and 48% at age 73 years. There was no detectable difference
between sexes for the time-to-event curves (P > 0.05). Among those
who did not develop ESRD, serum creatinine exceeded 1.5 mg/di in 0/40
less than 30 years. 4/22 aged 30 to 49 and 3/13 aged greater than 50
years.
New perspectives in toxemia of pregnancy. D. C. Catiran, J. Milligan,
and D. Moore. Department of Medicine and Obstetrics, Women's
College Hospital, University of Toronto, Toronto, Canada. Toxemia of
pregnancy classically occurs in primiparas in the third trimester, may
become fulminant rapidly unless the pregnancy is terminated, and
resolves within 8 weeks of delivery. For 1 year, we followed 22 known
pregravid normotensive patients who developed severe toxemia. They
illustrate a number of variations on this theme; 32% of patients were not
primigravida, 32% had onset of symptoms less than or equal to 28
weeks gestation (range, 24 to 36). thrombocytopenia( 120 x l09/liter)
was present in 40%, and serum creatinine was increased in 40% mean
1.7 mg% (range, 0.8 to 6.8). The resolution of different components is
outlined below.
Postpartum weeks
At presentation 1 2 4 8 12 24 36
Hypertensive (%) 100 73 55 27 20 15 5 0
Platelets (%) 40 10 5 0 — 0 0 0
Elevated Cr (%) 40 20 — 10 0 0 0 0
Proteinuria (%) 100 70 — 50 50 — 20 0
Alterations in red cell cation transport in hypertensive disorders of
pregnancy. A. B. Steingara', A. G. Logan, R. A. Bear, P. T. Flanagan,
and A. Chutzilias. University of Toronto, Department of Medicine,
Toronto, Ontario, Canada. The maximum rate of sodium-lithium
countertransport (SLC), a ouabain-insensitive membrane pathway for
sodium transport, was found to be significantly increased in 25 pregnant
normotensive subjects (PN) and l7 pregnant hypertensive patients
(PH); the mean was 0.37 0.02 (mean 5EM) and 0.47 0.03
mmoles/liter of RBC/hr, respectively, compared with 0.26 0.02 in 17
nonpregnant normotensive subjects (NN). SLC was positively correlat-
ed with gestational age in PN (r = 0.5, P <0.01) but not in PH (r = 0.27,
P > 0.29). SLC was significantly higher in PH than in PN even when
only those after the 28th week were compared (0.47 0.03 vs. 0.40
0.02, P < 0.05). On repeat sampling at least 12 weeks postpartum, the
mean SLC of 0.27 0.02 in seven previously PN and of 0.26 0.01 in
13 previously PH was not significantly different (P > 0.5). Moreover,
these values were not significantly different from the NN. Alterations in
red cell membrane transport are present in pregnancy and exaggerated
in pregnant hypertensive patients but are not found after the 12th week
postpartum. Disturbances of membrane cation transport may contrib-
ute to the pathogenesis of hypertensive disorders of pregnancy and
measurement during pregnancy may help to identify women at risk of
hypertensive disorders.
Adult polycystic kidney disease (APKD)—reappraisal of prognosis. D.
N. Churchill, J. C. Bear, J. Morgan, P. McManamon, and M. H.
Gault. Faculty of Medicine, McMaster University, Hamilton, Ontario
and Memorial University, St. John's, Newfoundland. The prognosis for
asymptomatic persons who have APKD diagnosed incidentally is
uncertain. Estimates range from 55% remaining asymptomatic through-
out life to 70% developing endstage renal failure (ESRD) by age 65. We
have studied 17 kindreds containing 313 living (excluding propositi) and
Despite the severity of presentation and intrauterine growth retardation
in many, the maternal mortality was 0 and fetal wastage only 9%. In
summary, this indicates severe toxemia can develop in the third
trimester. Resolution in renal function and hypertension can be much
delayed and hence management of the BP rather than early aggressive
investigation should be the rule for up to 9 months postpartum in this
group.
The frog syndrome: A new disorder of urea excretion. G. E. Plante, A.
Boucher, A. Lamontagne, and T. Nawar. Department of Medicine,
University Sherbrooke, Québec, Canada. A 38-year-old female was
seen for hyponatremia (PN,: 128 mEq/liter). A low blood urea (4 mg/dl)
was also documented. Following fluid restriction, PNa normalized but
blood urea remained low (2 to 4 mg/dl). During controlled dietary
nitrogen intake (10 g/day) urea clearance exceeded filtration rate
(Car,/GFR 1.42) indicating net tubular secretion of urea. The frog
normally secretes urea and this operation is abolished by probenecid.
When this drug was given to the patient (500 mglday during 3 days),
urea clearance fell by 50% and C,r./GFR dropped to a minimum value
of 0.4. Maximum urine osmolarity (Umax) was 443 mOsm/liter when
blood urea averaged 4 mg/dl. Urea infusion elevated blood urea to 28
mg/dl; partial correction of Un,,,.,, to 620 mOsm/liter was obtained. In
contrast, urea infusion impaired urinary dilution: Umin was 250 mOsm/
liter, compared to 155 mOsm/liter observed at lower blood urea. A
negative correlation (y = 1.74 to 0.31x, r = 0.941) was noted between
urinary urea excretion and free water clearance measured during water
load tests performed at low and normal blood urea levels, suggesting
that the dilution defect might be related to excess delivery of urea to the
thick limb. In conclusion, this patient has a unique defect of urinary
excretion of urea, characterized by a "frog-like" net tubular secretion
which is also inhibited by probenecid, a known marker of the organic
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acid transport secretory system. The abnormal pattern of urea excre-
tion is probably responsible for the defect of urine dilution mechanism
(and hyponatremia) observed in this peculiar patient.
Ultrafiltration capacity of the peritoneum as a function of the number
of episodes of peritonitis in patients on CAPD. C. H. Cole, D. Roy, and
S. Prichard. Royal Victoria Hospital, Montreal, Quebec, Canada.
There is concern that repeated episodes of peritonitis may interfere with
the capacity of the peritoneum to transport fluid. We have studied fluid
removal in 13 patients treated with CAPD for periods ranging from Ito
36 months. Over a 2.5 day period (ten exchanges) patients who had had
two or more episodes of peritonitis used an average of 3.7 1.2
hypertonic exchanges compared to 1.3 0.7 hypertonic exchanges in
patients who had had no peritonitis. Total fluid removal (including urine
volume) averaged 815 ml per 24 hr in patients who had no peritonitis
compared to 1791 ml/24 hr in patients who had two or more episodes of
peritonitis. Urine volume averaged 585 ml in the former group and 284
ml in the latter. The average fluid removal with a 4.25% Dianeal
exchange was 680 147 ml in patients with no previous peritonitis and
782 26 ml in patients with two or more episodes of peritonitis. We
conclude that as patients become more experienced with CAPD, they
gradually increase their fluid intake, compensating for this by increasing
the number of hypertonic exchanges which they use. A fall in urine
volume also necessitates the use of more hypertonic exchanges to stay
in fluid balance. There was no apparent decrease, in the patients we
studied, in ultrafiltration capacity of the peritoneum.
Factors affecting tobramycin kinetics across the peritoneum. G. Wit, H.
Rode/la, S. 1. Vas, and D. G. Oreopoulos. Toronto Western Hospital,
Toronto, Ontario, Canada. A loading dose of intraperitoneal tobramy-
cm (tobra) (1.7 mg/kg/2 liters) is part of the standard initial therapeutic
approach in CAPD patients with peritonitis. The introduction of high
volume, low frequency (3 x 3 liters) dialysis raised the question
whether the same loading dose should be administered irrespective of
dialysate volume (DV). We report the results of a study on the effect of
dialysate volume, osmolality, and the initial dialysate tobramycin
concentration (DTC) on the tobra transport kinetics across the peritone-
um as judged by the hourly serum tobramycin levels (STL) for the first 5
hr after intraperitoneal instillation of tobra containing dialysate. Three
bilaterally nephrectomized New Zealand rabbits were studied for each
set of DV, osmolality, and initial DTC. With dialysate glucose concen-
tration equaling 1.5% and DTC equaling 34 mg/liter, the 5th hr STL
were 6.9, 8.8, and 11.5 mg/liter when DV were 50 mI/kg, 100 mL/kg, and
150 mI/kg, respectively. With DV = 50 mI/kg, DTC = 34 mg/liter, the
5th-hr STL were 6.8 and 4.7 mg/liter when dialysate glucose concentra-
tion were 1.5 and 4.25%, respectively. With DV = 50 mI/kg and
dialysate glucose concentration equaling 1.5%, the 5th-hr STL were
2.2, 2.5, and 6.8 mg/liter when DTC were 11.3, 17, 34 mg/liter,
respectively. Our findings show that the rate of rise of plasma tobra is
proportional to dialysate tobra concentration and dialysate volume but
inversely related to dialysate osmolality. For CAPD patients with
peritonitis, we should aim for a standard initial dialysate tobramycin
concentration.
CAPD in Toronto—the first 5 years. C. Williams, D. Cattran, S.
Clayton, E. Cole, S. Fenton, K. Gutman, R. Khanna, S. Knight, A.
Manuel, J. Roscoe, C. Saiphoo, S. Tattersall, S. Vas, andD. Oreopou-
los. University of Toronto, Toronto, Ontario, Canada. CAPD was
initiated in Toronto in September 1977. Among four institutions, over
the first 5 years, 508 patients completed CAPD training (287 males, 221
females; mean age, 50.4 years; range, 6 to 78 years, 89 diabetic patients.
Determined by Life Table Analysis, the cumulative patient survival was
94, 82, 72, and 65% at 1, 2, 3, and 4 years. The corresponding technique
success rates were 81, 59, 45, and 35% (both deaths and transfers
considered treatment failures). By the end of October 1982, 304 patients
had left the CAPD program: transplantation, 105 (34.5%); deaths, 75
(24.7%); transfers, 115 (34.8%); lost to follow-up, 9 (3.0%). Peritonitis
was the most common reason for CAPD failure (42.6%). Cardiovascular
causes accounted for the largest number of deaths (42.7%). Diabetic
patients and patients over 60 had significantly higher mortality rates.
The rate of transfer was higher in elderly patients but not diabetic
patients. During 8,648 treatment months, there were 778 episodes of
peritonitis, an incidence of I episode/I 1.1 treatment months. The
incidence of peritonitis has decreased from I episode/6.5 treatment
months in 1977 to I episode/l4.l treatment months in 1982. CAPD
continues to be an effective and well-accepted dialysis modality,
permitting a large number of patients to dialyze at home.
The phenomenon of dialyser hypersensitivity and its modification in an
animal model. J. F. Walker, R. M. Lindsay, W. J. Sibbald, S. Peters,
and A. L. Linton. Victoria Hospital, London, Ontario, Canada. Dia-
lyser hypersensitivity is characterized by acute chest pain, hypoten-
sion, and dyspnea. The relationship between this and the more fre-
quently recognized leukopenia and hypoxia, is unknown. A sheep
model was used to examine this relationship where blood was exposed
to regenerated cellulose (RC), cuprophan (C), saponified cellulose
acetate (SCE), cellulose acetate (CA), and polyacrylonitrate (PAN), for
10 mm. Increasing volumes (I to 15 ml) of this blood were reinjected
and the effect on mean pulmonary artery pressure (PAP), neutrophil
count, and PaO2 followed. Increasing volumes of blood (contact time—
10 mm) caused progressive rise in PAP with C, SCE, and RC but little
effect with CA or PAN. The severity of neutropenia and hypoxia
mirrored the degree of acute pulmonary hypertension which was
associated with a fall in cardiac output, myocardial ischemia, and
arrhythmias. Its occurrence was unaffected by pre-animal treatment
with H1 and H2 receptor blockers, leukopenia (wcc < 1000) or
pretreating the blood to be surface-contacted with ASA. Blood pretreat-
ed with citrate, EDTA, and Mg EGTA, prior to surface contact blocked
the response as did pretreatment of the animal with indomethacin, 2
mg/kg. Surface-contacted plasma caused the phenomenon while heat-
inactivated and decomplemented plasma did not. The data indicate that
certain surfaces activate a plasma factor, which via the cyclo-oxygen-
ase system lead to an acute pulmonary hypertension fall in cardiac
output and hypoxia. Circulatory leukocytes are not necessary.
The long-term function of the gallbladder conduit in orthotopic liver
transplantation. C. H. Scudamore and R. Y. CaIne. University of
Cambridge, Addenbrooke 's Hospital, Cambridge, United Kingdom.
The gallbladder/conduit is the method of interposing the donor's
gallbladder between the donor common hepatic duct and the recipient
common bile duct to provide a tension-free biliary anastomosis for
orthotopic liver transplantation. The Cambridge/King's College Hospi-
tal experience in orthotopic liver transplantation is now in its 14th year.
The technical success of this procedure owed much to the solution of
the biliary drainage problem by the use of the gallbladder as a conduit,
introduced in 1976. This study investigated the complications of the
gallbladder conduit compared to other methods of biliary drainage and
investigated the function of the gallbladder conduit in otherwise healthy
liver transplant recipients. (1) Biliary complications, both early and
late, were significantly reduced in those patients receiving a gallbladder
conduit (53 conduit patients, 43 nonconduit patients. P = 0.01 by the
Fisher F test). (2) Complications in patients surviving longer than 6
months were reduced in those patients having had a gallbladder
conduit. (3) Five patients, who are well after having a gallbladder
conduit performed showed their gallbladder was able to concentrate
iopanoic acid taken orally and that the gallbladder was able to contract
after a fatty meal. All patients are long-term survivors. (4) Elevated
alkaline phosphatase and gamma glutamyl transpeptidase isoenzyme
determinations suggest a nonobstructive cause for their elevations.
Pump-assisted portal and inferior vena cava blood return in the
anhepatic phase of pig liver transplants. H. Bitter-Suermann, C. E.
Hope, J. A. Love, R. B. Leadon, D. C. G. Bet hune, A. S. MacDonald,
and B. Vair. Laboratory of Transplantation Biology, Department of
Surgery, Daihousie University, Halifax, Nova Scotia. The standard
techniques of orthotopic pig liver transplantation employ a portojugular
venous bypass without pump in the anhepatic phase of the recipient
operation. Using this technique, we found that the mean arterial blood
pressure dropped to very low levels because of an inadequate venous
return due to compartmentalization of blood distal to the cross-clamped
infrahepatic inferior vena cava (IVC). We attempted to improve the
situation by shunting both portal and infrahepatic IVC blood via a
venous return chamber to a roller pump and thence to the left external
jugular vein. With this measure, mean arterial blood pressure readings
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in the anhepatic phase of liver grafts remained in an optimal range.
Furthermore, the usually violent swings of blood gases and the acid-
base balance were minimized. Thus, the liver grafts upon revasculariza-
tion enjoyed a more physiological environment facilitating the intra- and
postoperative management of the animals. The described shunting
procedure is simple and clinically applicable.
The requirements for maintenance steroids in cyclosporine-treated
renal transplant recipients. The Canadian Transplant Study Group.
Department of Medicine, University of Western Ontario, London,
Ontario, Canada. At the time of transplant, 69 renal transplant recipi-
ents were randomized to receive either cyclosporin (Cy) and prednisone
(36 patients) or Cy alone (33 patients). Cy was given initially at a dose of
15 mglkg/day, and the dose was adjusted to achieve a Cy serum R1A
trough level between 50 and 300 nglml. Rejection episodes in both
groups were treated with a maximum of 4.5 g of MP per week.
Cytotoxic agents or ALG could not be used. Follow-up was 5 to 173
days. Estimated I year actuarial graft survival was 83.8% in the
prednisone group and 87.8% in the group without prednisone (P =
0.82). Other prognostic factors examined were: (1) living related donor
(94.1%), cadaveric donor (83.0%, P = 0.32), (2) no previous transplant
(89.8%), previous transplant (68.4%, P = 0.03), (3) 4 transfusions(87.5%), >4 transfusions (83.5%, P = 0.75), (4) machine perfused
(85.8%), not perfused (86.7%, P = 0.91), (5) rewarm time 35 mm
(87.8%) rewarm time >35 mm (81.8%, P = 0.46). Graft survival in
cadaveric first transplants was 89%. In the four patients receiving no
transfusions, there were no graft losses. There were two graft losses in
four patients with a perfusion time >24 hr and no graft losses in four
patients with a rewarm time >45 mm. Nine patients were switched to
azathioprine and prednisone. Eleven patients randomized into the
group without prednisone required no maintenance steroids. Sixteen
patients in the group without prednisone continued on Cy alone. There
was no detectable difference in infectious complications between the
two groups. Eleven patients developed a WBC < 3,500/mI.
Measurement and clinical relevance of cyclosporin blood levels. P. A.
Keown, C. R. Stiller, A. Laupacis, M. Stawecki, J. McMichael, W.
Howson, and G. Carruthers. To optimize the clinical measurement of
cyclosporin (Cy) blood levels, we examined the factors determining
distribution of Cy between the red cell, plasma, and serum, utilizing
both radioimmunoassay (RIA) and HPLC, and investigated the influ-
ence of time and temperature on Cy levels. At peak serum concentra-
tion (Cmax), 61% of the total blood Cy concentration is cell-bound, of
which the parent molecule represents 73.6 6.4%. Dissociation from
the erythrocyte pooi was time- and temperature-dependent: Dissocia-
tion equilibrium was maintained at 37°C in vitro, while at 22° or 6°C
increased erythrocyte binding decreased the measurable plasma con-
centration by 30%. Following plasma separation, the concentration
measured by RIA also depends on the temperature and time of
incubation: After incubation for 60 mm at 4°C, concentration diminishes
to 68.8 5.8% of control, whereas incubation for a similar period at
37°C increased measurable concentrations to 114 2% of control.
Erythrocyte binding was markedly influenced by hematocrit. Addition-
ally, intra-individual variation in serum concentration was inversely
related to hematocrit. The clinical events that could be correlated with
Cy serum levels were (I) the incidence of acute tubular necrosis (ATN)
(38% if the initial Cy level was <100 ng/ml, 68% if >400 ng/ml), (2)
acute hepatotoxicity, and (3) acute nephrotoxicity. The relationship of
serum Cy levels to chronic nephrotoxicity was less distinct. Mean
trough Cy levels in such episodes was 251 60 ng/ml, not significantly
different from that during preceding quiescence (214 36 nglml).
Toxicity, however, responded to a further decrease in Cy level.
Cadaveric renal transplantation in Manitoba—the last 8 years. J. R.
Jeffery, A. Downs, C. Lye, J. K. McKenzie, W. Paquin, E. Ramsey, D.
Rush, and A. E. Thomson. Transplant Program, Health Sciences
Centre and University of Manitoba, Winnipeg, Canada. The overall
results of the program from July 1975 to June 1983 are presented. The
effect of the following variables are discussed: (I) donor pretreatment
(PreRx) with 5 g of methylprednisolone (MP) and 7 g cyclophosphamide
(CY); (2) donor PreRx with 70 mg/kg of CY for 5.5 hr and 50 mg/kg of
MP for 3 hr; (3) retrospective and prospective transfusions (TO; (4)
cyclosporin.
No. done
% Survival
1 year
Patient/graft
5 years
All patients 163 90.3/64.7 78.5/54.1
1st graft 138 89.7/66.2 78.2/55.2
2nd graft 22 93.8/54.5 85.2/49.6
No Tf
Preop Tf
Prospective Tf
1st PreRx trial
Control
PreRx
2nd PreRx trial
Control
PreRx
Cyclosporin
46
92
34
80.3/49.0
93.6/73.7
96.8/82.4
72.3/44.1
80.8/60.6
—
34
37
84.8/70.3
90.9/52.9
74.2/59.5
80.8/47.1
23
17
92.0/73.9
91.0/81.9
In conclusion, Preop transfusions and cyclosporin have led to improve-
ments in survival.
Late renal transplant failure and azathioprine reductIOn. P. S. Parfrey.
T. A. Hutchinson, R. P. Lowry, J. Knaack, andR. D. Guttmann. Royal
Victoria Hospital, Montreal, Canada. To investigate the causes of late
graft failure we studied 123 patients who had kidney transplants that
functioned for more than 5 years. Following entry into the study (5 year
post-transplantation) the subsequent 5-year graft survival was 84% in 37
living related and 66% in 86 cadaveric recipients. Late failure of
transplants was observed in 16 cadaver and four living related recipi-
ents. The histology in the failed grafts was chronic rejection (N = 10),
recurrent crescentic glomerulonephritis (N = 1), a recurrent diabetic
glomeruloscerosis (N = 1) and focal sclerosis (N = I). Urological
disease predisposed to late graft failure in another patient. Histology
was not available in the remaining six patients. To assess whether
prolonged decreases in azathioprine (Az) played a role in late graft
failure, we compared 23 patients who had Az reduced for medical
reasons to below 100 mg/day for more than 1 year, with 37 patients who
did not have Az reduced. The control group was matched for year of
transplantation and serum creatinine (stable and 2 mg/dl at time Az
reduced). Ten patients in Az reduced group and one in control group
required dialysis; the likelihood of dialysis was significantly greater in
Az reduced group (P < 0.001). It was concluded that chronic rejection
was the most frequent cause of late renal transplant failure which
appears to be hastened by prolonged reduction of azathioprine.
The use of cyclosporin in cardiac transplantation. R. Devineni, C.
Stiller, R. 0. Heimbecker, P. Keown, W. J. Kostuk, M. D. Silver, and
N. McKenzie. University Hospital, London, Ontario, Canada. Since
1981, we have performed ten orthotopic heart transplants using cyclo-
sporin (Cy) and prednisone as immunosuppressants. Six of the recipi-
ents had terminal congestive cardiomyopathy and four had ischemic
cardiac dysfunction. Their ages range from 18 to 52. Seven of the
recipients are alive and well with a followup period of one to 24 months.
One patient died on day 40 post-transplant of acute pancreatitis and
fulminating peritonitis. One patient died on day 46 of acute rejection.
Immunological studies and cardiac histology prior to the acute episode
had not revealed any evidence of rejection. The third mortality oc-
curred immediately post-transplant due to acute right ventricular fail-
ure. Two further episodes of rejection (2070 patient days at risk) were
diagnosed by cardiac histology and treated successfully. Cy-induced
reversible nephrotoxicity occurred in seven of ten patients, two of
whom required dialysis. We conclude that (1) Cy is a potent immuno-
suppressive agent, (2) close monitoring of blood levels is essential to
achieve appropriate immunosuppression with least toxicity, (3) risk of
infection has been greatly reduced with Cy, and (4) in selected patients
cardiac transplantation provides satisfactory and lasting palliation.
Current results
First graft
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Donor-specific preformed cytotoxic cells: No contraindication for kid-
ney transplantation. T. Kovithavongs and J. B. Dossetor. Departments
of Medicine and Laboratory Medicine, University of Alberta, Edmon-
ton, Alberta, Canada. Donor-specific preformed cytotoxic antibodies
are known to be harmful in renal transplantation. Evidence over the last
several years suggests that the presence of cytotoxic cells as detected
by lymphocyte-mediated cytotoxicity (LMC) against donor at the time
of transplantation is also associated with a poor outcome. Review of2l I
renal allografts performed in the last 10 years shows a positive LMC
crossmatch in 20, or 9.5% (LMC +ve test has a cytotoxic index of over
1.2), without concomitant presence of cytotoxic antibody. Sixteen of
these 20 patients had early graft rejections. The degree of positivity in
the cytotoxic index did not correlate with graft outcome. However, in
this group, graft outcome was good if methyl-prednisolone (MP) was
given at the time of transplantation. In seven patients who did not
receive MP, two grafts never functioned, two were rejected in 6 weeks,
one had multiple rejections and was lost at 1 year, and only two had
graft survival longer than 3 years. In contrast, of the 13 patients who
received MP at the time of transplantation, only one was rejected at 6
weeks, the others have good functioning grafts despite delayed function
of up to 3 weeks in eight of them. Seven have no further rejections for
over 3 years. Thus, the presence of donor-specific preformed cytotoxic
cells is not a contraindication to kidney transplantation provided that
the patients receive MP at the time transplantation is carried out.
Experience with fine needle aspiration (FNA) cytology in evaluating
kidney transplants. P. Belitsky and R. Gupta. Kidney Transplant Unit
and Department of Pathology, Victoria General Hospital, Halifax,
Nova Scotia. FNA of transplanted kidneys provides a rapid, safe,
convenient, and readily repeatable method for obtaining kidney sam-
ples to monitor intrarenal events after transplantation. Parenchymal
and infiltrating cells are obtained with each aspirate and analyzed
cytologically. To date we have performed over 100 aspirations in over
50 human transplant recipients without complications. We have found
the technique useful to establish the diagnosis and assess the evolution
of acute cellular rejection, acute tubular necrosis (ATN), and cyclospo-
rin (CYA) nephrotoxicity. The reliability in diagnosing acute cellular
rejection is suggested by correlation with clinical course and findings on
clinically indicated core needle biopsies in patients and by parallel FNA
and core needle biopsies of renal allografts and autografts in dogs.
Changes of ATN are less specific, although the nature and intensity of
renal tubular cell changes are helpful adjuncts in establishing the
diagnosis. Characteristic cytologic changes may be noted in renal
tubular cells of patients with potential CYA nephrotoxicity and these
changes may disappear with improvement in renal function when CYA
is discontinued. FNA cytology may therefore represent a mechanism
for monitoring and studying CYA nephrotoxicity after transplantation.
The FNA technique is potentially useful not only in managing patients
but also as a research technique to study in situ renal events after
transplantation.
Monitoring the effect of cyclosporin immunosuppression on lymphocyte
subsets by flow cytometry and monoclonal antibodies. R. Mazaheri, C. R.
Stiller, P. A. Keown, N. McKenzie, R. Coles, A. Hellstrom, W.
Howson, and W. Kostuk. University Hospital, University of Western
Ontario, London, Ontario, Canada. The mode of action of immunosup-
pression by cyclosporin (CyA) is not yet fully elucidated. Using flow
cytometry and monoclonal antibodies, we sequentially examined the
alterations in lymphocyte subsets, which occur in the peripheral blood
in association with long-term (>8 weeks) CyA-therapy following renal
and cardiac transplantation. Lymphocytes were obtained from normal
laboratory personnel, uremic patients and allograft recipients on either
cyclosporin (CyA + prednisone) or standard therapy (azathioprine +
prednisone). T lymphocyte subsets and la-positive cells were defined
by the OKT-monoclonal antibodies and an alloantiserum. Lymphocyte-
mediated cytotoxicity (LMC) was carried out by the 51Cr-release assay
against donor cells. Results showed that the OKT4/T8 ratio in 12
patients on CyA for longer than 8 weeks (renal, 1.0 0.1; cardiac, 0.8
0.3) was significantly lower than normal (1.8 0.5, P < 0.02) or
pretransplant (2.0 0.9, P < 0.01). This depression of the ratio was
particularly marked (0.5 0.3) in five renal patients, who also exhibited
significantly augmented levels of OKT3 (85% 6, P < 0.05) and OKT8-
positive cells (55% 9.9, P 0.01). However, all patients showed
decreased mean Ia-reactivity and negative LMC. Thus, the study
indicates that CyA may permit the induction of suppressor T cells,
while simultaneously inhibiting helper T lymphocytes and preventing
cytotoxic T lymphocyte generation.
Rejection episodes and lymphocyte responses in transplant patients
given rabbit antithymocyte serum (RATS). D. Landsberg, C. M. Ng,
and C. J. Cardella. Toronto Western Hospital, Toronto, Ontario,
Canada. A significant number of patients given RATS do not have
acute rejection episodes (RE). To identify such patients, the lympho-
cyte responses using a constant cell number, were measured in 16
transplant recipients (R) before and during therapy with RATS, predni-
sone, and azathioprine. The degree of suppression of R lymphocytes to
the mitogens PHA and CON-A and to third party cells in a mixed
lymphocyte response (MLR) was determined before and after therapy
and compared to the number of acute RE. Fifteen of the 16 patients
have functioning grafts. Eight did not have a RE (group A) and eight had
one or more RE (group B). After therapy the degree of suppression to
mitogens was 83 35% in group A as compared to 37 38% in group B
(P 0.01). After therapy in the 11 patients studied, the degree of MLR
suppression was 92 7% in group A (six patients) and 12 91% in
group B (five patients) (P 0.03). To investigate the mechanism of the
suppression, R cells were mitomycin-treated and used as targets in
MLR. After therapy the degree of suppression induced by the R cells as
targets was 54 35% in group A and SI 47% in group B (P = NS).
The degree of suppression of R lymphocyte responses to mitogens and
in MLR correlated with the lack of RE. The ability of RATS-treated R
cells to stimulate normal cells in an MLR was suppressed equally in
those patients with and without RE. Thus, the absence of RE and the
degree of suppression of R lymphocyte responses is likely not due to
masking of surface antigens alone.
Transplant monitoring with monoclonal antibodies to human T cell
subsets by 51-CR release in complement-dependent cytotoxicity (CDC-
CR): A preliminary study. T. Kovithavongs and J. B. Dossetor.
Departments of Medicine and Lab Medicine, University of Alberta,
Edmonton, Alberta, Canada. Using three monoclonal antibodies (Mab)
of IgG2 subclass which mediate complement-dependent lysis, a new test
system has been developed for quantitating T helper (TH) to cytotoxic/
suppressor (TCS) subsets in peripheral blood (PBL) by 51-Cr release.
Mab 51.1 marks TCS, Mab 66.1 marks TH while Mab 7.2 reacts with
DR molecules on B cells and monocytes. In 30 normal subjects, mean
percentages of CDC-Cr by 51.1 and 66.1 was 18(10 to 30) and 27(13 to
48) giving a mean TH:TCS ratio of 1.7(0.8 to 4.0). In 42 dialysis patients
pretransplant, this ratio was 2.4 (0.6 to 6.5). No difference was found in
terms of graft outcome whether the pre-transplant TH:TCS ratio was
>2.4 (N = 18, good outcome, II), or <2.4 (N = 24, good outcome, 20),
P> 0.1. Serial studies were carried out in Il patients of whom six had
clearcut rejection episodes. No consistent change of TH/TCS ratio was
observed in association with rejection; rejection episodes were not
significantly associated with a rise in TH:TCS ratio. Contrary to
previous reports, a marked increase in TCS subset, with reversal of the
ratio, was found in the only patient who rejected her renal allograft;
ratios <1.0 occurred prior to and for 4 weeks following transplant
nephrectomy. More importantly, strong donor specific lymphocyte-
mediated cytotoxicity was correlated with this reversed ratio, indicating
that the reversal in this patient was due to the overflow of cytotoxic T
cells into the blood. Caution is advised against interpreting TH:TCS
ratio without proper functional studies in renal transplant monitoring.
Studies on rejection of heart grafts transplanted across isolated class 1
MHC disparities. R. P. Lowry and J. H. Blackburn. Royal Victoria
Hospital, McGill University, Montreal, Quebec, Canada. We have
previously established that delayed type hypersensitivity (DTH) and
cytotoxic effectors (Tc) may independently effect rejection of heart
grafts transplanted across a full haplotype disparity. The present study
was undertaken to delineate the mechanism of graft rejection in the
presence of isolated class I disparities using PVG (RT1ACBC) and
congenic recombinant PVG RT1n (RT1ABC) inbred rat strains. PVG
rats failed, however, to reject PVG RTI' heart grafts in observation
periods of 28 to 43 days (N = 5). Although heart grafts bearing isolated
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class 2 disparities (PVG RTln — PVG RTl) induce a brisk humoral
response and Tc, with specificity for the class 2 disparity, PVG
recipients of PVG RTId heart grafts lack detectable antibody (N 8) or
Tc (N = 3). Since antibody formation to the class I alloantigen in the
PVG RTl -. PVG combination is under Ir gene control (c and u
haplotypes being low and high responders, respectively; further studies
were performed using (WF x PVG)F1 (RTIAUBU x RTIAB) recipi-
ents. (WF x PVG)F1 recipients reject PVG RTI1 heart grafts in 11.3
1.2 days (N = 3) in association with the development of both Tc and
specific antibody: the latter shown (RBC absorbtion) to be specific for
RTIA encoded specificities. Mixed lymphocyte cultures provided no
insight as to why the F recipient effected heart graft rejection, while the
parental PVG strain failed to respond to alloantigens of the graft, being
negative in both instances. Immune response (Ir) genes, controlling
both the serologic response and Tc generation, may determine the fate
of transplanted organ grafts bearing isolated class I disparities.
Immunologic basis of the variability of host responses to minor
histocompatibility antigens. G. Carayanniotis and P. F. Ha/loran. H.
Tanenhaum Department of Research, Mount Sinai Hospital, Toronto,
Ontario, Canada. Hosts receiving MHC-matched grafts differ consider-
ably in the strength of their immune response to the minor histocom-
patibility antigens of the grafts. The basis of this was investigated in a
mouse tumor graft system in which the various strains and hybrids
received H-2 identical, MiHA-incompatible P8I5Y tumor graft. Marked
differences in susceptibility were observed, some of which could be
attributable to the number of mismatched MiHA. But other differences
reflected differences in host responsiveness to the same MiHA. The
immunologic basis of these differences was investigated and found to
correlate with different levels of cytotoxic T lymphocyte (CTL) respon-
siveness. In one combination the differential responsiveness was asso-
ciated with differences in CTL precursor frequency in limiting dilution
analysis. In other combinations the differences in CTL response were
not mirrored by differences in CTL precursor frequency and probably
are due to different levels of helper activity. The results suggest that at
least three factors control the strength of the CTL response to multiple
MiHA: (I) the number of incompatible MiHA; (2) the CTL precursor
frequency to the MIHA; and (3) immunoregulatory factors other than
precursor frequency, possibly helper activity. Both precursor frequen-
cy and helper activity may be under MHC control.
Transfer of specific transplantation tolerance in rats as judged by
cardiac allograft survival. J. P. Smith, S. M. Stepkowski. W. R.
Duncan. and H. Bitter-Suermann. Laboratory of Transplantation Biol-
ogy, Department of Surgery, Daihousie University, Halifax, Nova
Scotia. Vascularized spleen allografts from WAG (RTl) to AGUS
(RTI') rats survive indefinitely and convey specific transplantation
tolerance toward donor-type antigens. We investigated the cellular
basis of this tolerant state in classical adoptive transfer of tolerance
experiments. Spleen and/or lymphnode cells (2.5 to 3.5 x l0) from
tolerant AGUS were injected intravenously into normal uncompro-
mised AGUS. The success of transfer of tolerance was assessed by
WAG heterotopic cardiac allografts. Seventy-five percent of such grafts
have been surviving for up to 133 days. Cardiac control allografts were
rejected within 8 days as were third-party BN (RTl) cardiac allografts.
The phenotypical and genotypical characteristics of the cells involved
in this transfer of tolerance are currently being investigated.
Mixed leukocyte reaction responses of thoracic duct lymphocytes from
tolerant spleen grafted rats. S. M. Stepkow.ski, J. P. Smith, W. R.
Duncan, and H. Bitter-Suermann. Laboratory of Transplantation Biol-
ogy, Department of Surgery, Dalhousie University, Halifax, Nova
Scotia. Whole-organ spleen allografts from inbred WAG (RTl') to
AGUS (RTI1) rats survive indefinitely and subsequently produce a state
of specific transplantation tolerance. Thoracic duct lymphocytes (TDL)
from tolerant rats were examined for the presence of suppressor cells
by studying their ability to respond in the mixed leukocyte reaction
(MLR) toward donor-type WAG or third-party BN (RTl) stimulator
cells. The results indicated that MLR responses of TDL from tolerant
animals against WAG stimulators were suppressed by 90% while the
responses to BN stimulators remained normal. In cell co-culture
experiments irradiated tolerant (T-TDL) or naive (N-TDL) were added
in a 1:1 ratio to normal. syngeneic AGUS TDL and cultured in the MLR
with WAG or BN stimulator cells. In these mixing experiments T-TDL
caused a 97% suppression of normal AGUS MLR responses while N-
TDL did not. The results suggest that T-TDL contains a radioresistant
population of suppressor cells of yet unknown phenotype or genotype,
able to exhibit suppressive activity at the level of alloantigen recogni-
tion. Studies are in progress to look into their suppressive properties at
the effector arm of alloreactivity.
Graft-versus-host disease (GVHD) induces expression of Ia antigens in
renal tubular cells in mouse kidney. A. Wadgymar, J. Urmson, P.
Wi/son, and P. Ha/loran. H. Tannenbaum Department of Research,
Mount Sinai Hospital, Toronto, Ontario, Canada. Ia antigen expres-
sion in kidney is of interest because of the role that Ia may play in
regulation of intrarenal immune responses. To determine whether
immunologic stimuli can alter renal Ia expression, we induced acute
GVHD in A.TL mice by irradiation and reconstitution with allogeneic
(A.SW) bone marrow and spleen cells, which differ at the I and D
regions of the H-2 complex. At day 10 after reconstitution, absorption,
indirect immunofluorescence (hF), and peroxidase anti-peroxidase
(PAP) experiments were performed, to quantitate and localize ha.
Absorption studies with anti-Ia serum revealed that kidneys of animals
with GVHD had a tenfold increase in the quantity of Ia, compared to
normal animals. This change was not seen in irradiated or in syngenei-
cally reconstituted control mice. By hF and PAP techniques, and
irradiated control mice showed peritubular staining, and syngeneic
control mice showed occasional tubular cell staining. However, allo-
geneically reconstituted animals with GVHD showed strong positive
staining in the cytoplasm of renal tubular cells with A.TH anti-A.TL
and anti-Ia.2. The tubular cells may have become Ia-positive by passive
uptake of Ia, or more probably, by derepression of Ia biosynthesis in
the tubule cells. We conclude that renal tubule Ia expression may be
induced during immunologic reactions.
